Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 226 participants.
Also called NCT07797036
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 2/3
- Enrolled
- 226 participants
- Registry
-
NCT07797036
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07797036. Randomized; no masking; primary purpose prevention. Start 2027-09-01 (anticipated); primary completion 2030-09-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
- Condition
- Gestational Diabetes Mellitus (GDM)
- Condition
- Metabolic Syndrome
- Intervention (Drug)
- Semaglutide (Wegovy) weekly injection
- Lead sponsor
- University of Massachusetts, Worcester
Record details
- Record id
cardio:ct-nct07797036- Content hash
56cf97aefc5556ddcc828d8266a7d8a754bd6b7aadee9c769c46ce92044899cf